vol way too low for stock with upcoming Ph 2 in a field where there is no or little treatment/cure and multi billion dollar potential.
plus the R/S. NO CEO in their right mind would do a R/S right before phase 2 top line data, if results are going to be bad and stock drop under $5 again. The reason he just did R/S is to keep stock over $5 so that MM can buy.
they hit $12 before Ph 2 results. AVXL market cap is somewhere about $250M...I see an easy double till Nov 7th.
Of course AVXL success is much stronger, we are 4X vs. standard care today...PRAN was measuring against placebo, and that too with science that did not work.
Plus see the difference..PRAN had CEO announce Ph 2....AVXL is having their hospital director fly from Austrialia to Barcelona to present. BIG DIFFERENCE. Plus if AVXL is going to give bad news, they would not present partial 52 weeks data. That would make no sense if 36 days data for the 32 patients did not do really well.
Am expecting a double from here till Nov 7th on the same lines.
actually I think they will have both 3months and 6 months data. Remember they started the ph 2 back in January, so it has been 9-10 months already.
Any good news at 3 and 6 months will bode very well against donepezil.
that is already proven. But if you look at their preso, after 6 months, the standard is getting close to 2-73 was at 36 days. So the big question is...what is the % effectiveness of 2-73 after 6 months, vs 6 months of standard ? I am glad they are going to give 6 months, and 52 weeks partial results too. That will show longer term how effective 2-73 is going to be with daily dosing.
they wanted to get it cheap for the upcoming results. This should be illegal.
I can add the link here...just search for it. This is the main part of the article. Plus the doctor says he is cautiously optimistic.
This drug seems to improve electrical markers by four times more than the current standard of care drug, which is a medication called donepezil (Aricept),” Prof Macfarlane said.
The result, which came after 36 days of therapy, is already higher than what donepezil reaches after six months of taking it continuously.
“We’ve also had patients and their carers reporting improvements in their thinking, increased alertness and improvement in their organisation and independence,” Prof Macfarlane said.
Patients and carers were so impressed with the changes that they are now trying to double the period of time they can access the drug.
BTW, he is going to Barcelona to present complete 2A results.
why would he fly doctor from Austrialia to Barcelona to present the results ? All this means results for 2A part A and B will be really good. Read between the leaves.
we are doing the reverse..we are moving up because fundamentals are getting much better....
why bother ? He is doing it because he knows its going to be GREAT. And funds only buy stocks over $5, and not on pink OTC. He is preparing for the future. He says it himself - uplisting is for sharing into the future success.
market cap 1.3 billion...buy AVXL for 3x current market cap.